Mizuho Maintains Buy on Coherus BioSciences, Lowers Price Target to $21
Mizuho analyst Salim Syed maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price target from $28 to $21.
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
FDA Approved Coherus’ CIMERLI as the First and Only Interchangeable Biosimilar to Lucentis for All Five Indications, with 12 Months of Interchangeability Exclusivity
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S.